Table 1.
Baseline characteristics of various subsets of the study population. PAH = Pulmonary arterial hypertension, PVH = Pulmonary venous hypertension, LD-PH = Lung disease associated pulmonary hypertension, CTEPH = Chronic thromboembolic pulmonary hypertension, PH-Misc = Pulmonary hypertension due to miscellaneous causes, WHO FC = World health organization functional class, PH = Pulmonary hypertension, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, RVSP = Right ventricular systolic pressure, RV dysfunction = Right ventricle systolic dysfunction, CCB = Calcium channel blockers, HF = Heart failure, ACEI = Angiotensin converting enzyme inhibitors, ARB = Angiotensin receptor blockers, MRA = Mineralocorticoid receptor antagonists, OAC = Oral anticoagulants.
| Total (N = 2003) | PAH (N = 317) | PVH (N = 1294) | LD-PH (N = 293) | CTEPH (N = 73) | PH-Misc (N = 26) | |
|---|---|---|---|---|---|---|
| Age, mean (SD) | 55.7 (15.9) | 47.6(17.1) | 56.3(15.5) | 62.9(12.8) | 50.7(13.8) | 56.6(17.7) |
| Females, n (%) | 1044 (52) | 198(62.6) | 666 (51.5) | 118 (40.2) | 45 (61.6) | 17 (65.4) |
| Baseline symptom class, n (%) | ||||||
| WHO FC I | 105(5.2) | 34 (10.7) | 54 (4.2) | 12 (4.1) | 4 (5.5) | 1 (3.8) |
| WHO FC II | 1313(65.5) | 201(63.4) | 900 (69.5) | 155 (52.9) | 37 (50.7) | 20 (77) |
| WHO FC III | 489(24.5) | 72 (22.7) | 288 (22.2) | 103 (35.2) | 24 (32.8) | 2 (7.7) |
| WHO FC IV | 96(4.8) | 10 (3.2) | 52 (4.1) | 23 (7.8) | 8 (11) | 3 (11.5) |
| Family history of PH, n (%) | 21 (1.1) | 2(0.6) | 12 (0.9) | 6 (2) | 1 (1.4) | 0 |
| SBP, mean (SD) | 129.4 (21.3) | 127.2(21) | 129.1(21.5) | 132.6(19.4) | 128.1(20.8) | 135.7(20.4) |
| DBP, mean (SD) | 81.0 (8.3) | 81(8.2) | 80.6(8.5) | 82.3(7.6) | 81(8.6) | 83.5(8.4) |
| RVSP, mean (SD) (mmHg) | 68.2 (17.9) | 74.5(21) | 66.7(16.6) | 67.9(18.1) | 69.8(20.2) | 63.4(15.4) |
| Right heart failure, n (%) | 371 (18.5) | 57 (18) | 242 (18.7) | 56 (19.1) | 9 (12.3) | 7 (27) |
| RV dysfunction on echo, n (%) | 186 (9.3) | 32 (10) | 120 (9.3) | 24 (8.2) | 8 (11) | 2 (7.7) |
| Drug therapy, n (%) | ||||||
| CCB | 87 (4.3) | 13 (4) | 57 (4.4) | 12 (4.1) | 4 (5.5) | 1 (3.8) |
| HF drugs (diuretics/ACEI/ARB/MRA) | 789 (39.4) | 109 (34.4) | 534 (41.2) | 110 (37.5) | 25 (34.2) | 11 (42.3) |
| OAC | 335 (16.7) | 58 (18.3) | 224 (17.3) | 36 (12.3) | 15 (20.5) | 2 (7.7) |
| Antiplatelets | 612 (30.5) | 66 (20.8) | 427 (33) | 85 (29) | 24 (32.8) | 10 (38.5) |
| Specific vasodilator drugs | ||||||
| Monotherapy | 318 (15.9) | 84 (26.5) | 162 (12.5) | 53 (18.1) | 14 (19.2) | 5 (19.2) |
| Combination therapy | 36 (1.8) | 14 (4.4) | 12 (0.9) | 9 (3.1) | 1 (1.4) | 0 |